Target Price | $65.40 |
Price | $43.93 |
Potential |
48.87%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Corcept Therapeutics Incorporated. 2025 .
The average Corcept Therapeutics Incorporated. target price is $65.40.
This is
48.87%
register free of charge
$78.00
77.56%
register free of charge
$45.00
2.44%
register free of charge
|
|
A rating was issued by 5 analysts: 5 Analysts recommend Corcept Therapeutics Incorporated. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Corcept Therapeutics Incorporated. stock has an average upside potential 2025 of
48.87%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 482.38 | 661.05 |
20.04% | 37.04% | |
EBITDA Margin | 22.46% | 20.07% |
21.94% | 10.62% | |
Net Margin | 20.34% | 17.71% |
9.99% | 12.95% |
5 Analysts have issued a sales forecast Corcept Therapeutics Incorporated. 2024 . The average Corcept Therapeutics Incorporated. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Corcept Therapeutics Incorporated. 2024 . The average Corcept Therapeutics Incorporated. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Corcept Therapeutics Incorporated. Analysts have issued a net profit forecast 2024. The average Corcept Therapeutics Incorporated. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.94 | 1.12 |
8.05% | 19.15% | |
P/E | 39.18 | |
EV/Sales | 6.24 |
5 Analysts have issued a Corcept Therapeutics Incorporated. forecast for earnings per share. The average Corcept Therapeutics Incorporated. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Corcept Therapeutics Incorporated. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Corcept Therapeutics Incorporated....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.